{"name":"Purdue Pharma LP","slug":"purdue-pharma-lp","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":800000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Subutex","genericName":"BUPRENORPHINE","slug":"buprenorphine","revenue":800000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"1981-01-01","label":"Subutex first approved","drug":"Subutex","drugSlug":"buprenorphine","type":"approval","sentiment":"positive"},{"date":"1999-01-01","label":"Chirocain first approved","drug":"Chirocain","drugSlug":"levobupivacaine","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-07-31","label":"Subutex patent expiry (Formulation)","drug":"Subutex","drugSlug":"buprenorphine","type":"patent_expiry","sentiment":"negative"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-10","label":"Subutex patent expiry (Formulation)","drug":"Subutex","drugSlug":"buprenorphine","type":"patent_expiry","sentiment":"negative"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-06","label":"Subutex patent expiry (Formulation)","drug":"Subutex","drugSlug":"buprenorphine","type":"patent_expiry","sentiment":"negative"},{"date":"2031-06-06","label":"Subutex patent expiry (Formulation)","drug":"Subutex","drugSlug":"buprenorphine","type":"patent_expiry","sentiment":"negative"},{"date":"2031-06-06","label":"Subutex patent expiry (Method of Use)","drug":"Subutex","drugSlug":"buprenorphine","type":"patent_expiry","sentiment":"negative"},{"date":"2031-06-06","label":"Subutex patent expiry (Formulation)","drug":"Subutex","drugSlug":"buprenorphine","type":"patent_expiry","sentiment":"negative"},{"date":"2031-06-06","label":"Subutex patent expiry (Method of Use)","drug":"Subutex","drugSlug":"buprenorphine","type":"patent_expiry","sentiment":"negative"},{"date":"2031-06-06","label":"Subutex patent expiry (Method of Use)","drug":"Subutex","drugSlug":"buprenorphine","type":"patent_expiry","sentiment":"negative"},{"date":"2031-06-25","label":"Subutex patent expiry (Formulation)","drug":"Subutex","drugSlug":"buprenorphine","type":"patent_expiry","sentiment":"negative"},{"date":"2031-09-05","label":"Subutex patent expiry (Formulation)","drug":"Subutex","drugSlug":"buprenorphine","type":"patent_expiry","sentiment":"negative"},{"date":"2032-01-06","label":"Subutex patent expiry (Formulation)","drug":"Subutex","drugSlug":"buprenorphine","type":"patent_expiry","sentiment":"negative"},{"date":"2032-07-26","label":"Subutex patent expiry (Formulation)","drug":"Subutex","drugSlug":"buprenorphine","type":"patent_expiry","sentiment":"negative"},{"date":"2032-07-26","label":"Subutex patent expiry (Formulation)","drug":"Subutex","drugSlug":"buprenorphine","type":"patent_expiry","sentiment":"negative"},{"date":"2032-07-26","label":"Subutex patent expiry (Formulation)","drug":"Subutex","drugSlug":"buprenorphine","type":"patent_expiry","sentiment":"negative"},{"date":"2032-07-26","label":"Subutex patent expiry (Method of Use)","drug":"Subutex","drugSlug":"buprenorphine","type":"patent_expiry","sentiment":"negative"},{"date":"2032-07-26","label":"Subutex patent expiry (Formulation)","drug":"Subutex","drugSlug":"buprenorphine","type":"patent_expiry","sentiment":"negative"},{"date":"2032-07-26","label":"Subutex patent expiry (Formulation)","drug":"Subutex","drugSlug":"buprenorphine","type":"patent_expiry","sentiment":"negative"},{"date":"2035-11-06","label":"Subutex patent expiry (Method of Use)","drug":"Subutex","drugSlug":"buprenorphine","type":"patent_expiry","sentiment":"negative"},{"date":"2035-11-06","label":"Subutex patent expiry (Method of Use)","drug":"Subutex","drugSlug":"buprenorphine","type":"patent_expiry","sentiment":"negative"},{"date":"2038-06-22","label":"Subutex patent expiry (Method of Use)","drug":"Subutex","drugSlug":"buprenorphine","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":800000000,"percentOfTotal":100,"drugCount":9,"colorKey":"oncology","drugs":[{"name":"Subutex","genericName":"BUPRENORPHINE","slug":"buprenorphine","indication":"Opioid Dependence Treatment","status":"marketed","revenue":800000000},{"name":"Oxycodone HCl controlled-release tablets","genericName":"Oxycodone HCl controlled-release tablets","slug":"oxycodone-hcl-controlled-release-tablets","indication":"Moderate to severe chronic pain requiring continuous opioid therapy","status":"phase_3"},{"name":"Buprenorphine transdermal delivery system","genericName":"Buprenorphine transdermal delivery system","slug":"buprenorphine-transdermal-delivery-system","indication":"Moderate to severe chronic pain","status":"phase_3"},{"name":"Chirocain","genericName":"LEVOBUPIVACAINE","slug":"levobupivacaine","indication":"Anesthesia for cesarean section","status":"marketed"},{"name":"HYD","genericName":"HYD","slug":"hyd","indication":"Moderate to moderately severe pain","status":"marketed"},{"name":"OXY/APAP","genericName":"OXY/APAP","slug":"oxy-apap","indication":"Moderate to severe acute pain","status":"phase_3"},{"name":"Oxycodone HCl controlled-release","genericName":"Oxycodone HCl controlled-release","slug":"oxycodone-hcl-controlled-release","indication":"Moderate to severe chronic pain requiring continuous opioid therapy","status":"marketed"},{"name":"Oxycodone/Naloxone controlled-release","genericName":"Oxycodone/Naloxone controlled-release","slug":"oxycodone-naloxone-controlled-release","indication":"Moderate to severe chronic pain requiring continuous opioid therapy","status":"phase_3"},{"name":"Placebo oxycodone/acetaminophen tablets","genericName":"Placebo oxycodone/acetaminophen tablets","slug":"placebo-oxycodone-acetaminophen-tablets","indication":"Control arm in clinical trials for opioid/acetaminophen combination pain relief","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Buprenorphine transdermal patch","genericName":"Buprenorphine transdermal patch","slug":"buprenorphine-transdermal-patch","indication":"Other","status":"marketed"},{"name":"Placebo to match BTDS","genericName":"Placebo to match BTDS","slug":"placebo-to-match-btds","indication":"Matching placebo for BTDS clinical trials","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Adhansia XR","genericName":"Adhansia XR","slug":"adhansia-xr","indication":"Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6 years and older","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Ketoconazole tablet","genericName":"Ketoconazole tablet","slug":"ketoconazole-tablet","indication":"Treatment of systemic fungal infections such as blastomycosis, coccidioidomycosis, histoplasmosis, and aspergillosis","status":"phase_2"}]}],"pipeline":[{"name":"Subutex","genericName":"BUPRENORPHINE","slug":"buprenorphine","phase":"marketed","mechanism":"Buprenorphine binds to mu-opioid receptors as a partial agonist and kappa-opioid receptors as an antagonist.","indications":["Opioid Dependence Treatment"],"catalyst":""},{"name":"Oxycodone HCl controlled-release tablets","genericName":"Oxycodone HCl controlled-release tablets","slug":"oxycodone-hcl-controlled-release-tablets","phase":"phase_3","mechanism":"Oxycodone HCl binds to opioid receptors in the central nervous system to block pain signal transmission and provide analgesia.","indications":["Moderate to severe chronic pain requiring continuous opioid therapy","Postoperative pain management"],"catalyst":""},{"name":"Buprenorphine transdermal patch","genericName":"Buprenorphine transdermal patch","slug":"buprenorphine-transdermal-patch","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Adhansia XR","genericName":"Adhansia XR","slug":"adhansia-xr","phase":"marketed","mechanism":"Adhansia XR is a combination of amphetamine salts and guanfacine that increases dopamine and norepinephrine activity while also activating alpha-2A adrenergic receptors to improve attention and reduce hyperactivity and impulsivity.","indications":["Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6 years and older"],"catalyst":""},{"name":"Buprenorphine transdermal delivery system","genericName":"Buprenorphine transdermal delivery system","slug":"buprenorphine-transdermal-delivery-system","phase":"phase_3","mechanism":"Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to opioid receptors in the central nervous system to produce analgesia and reduce opioid cravings.","indications":["Moderate to severe chronic pain","Opioid use disorder (maintenance treatment)"],"catalyst":""},{"name":"Chirocain","genericName":"LEVOBUPIVACAINE","slug":"levobupivacaine","phase":"marketed","mechanism":"Cytochrome P450 2D6","indications":["Anesthesia for cesarean section","Local anesthesia","Major Nerve Block for Surgery","Regional Anesthesia for Labor Pain","Regional Anesthesia for Postoperative Pain"],"catalyst":""},{"name":"HYD","genericName":"HYD","slug":"hyd","phase":"marketed","mechanism":"Hydrocodone is an opioid agonist that binds to mu opioid receptors in the central nervous system to produce analgesia and cough suppression.","indications":["Moderate to moderately severe pain","Cough suppression"],"catalyst":""},{"name":"Ketoconazole tablet","genericName":"Ketoconazole tablet","slug":"ketoconazole-tablet","phase":"phase_2","mechanism":"Ketoconazole is a broad-spectrum antifungal agent that inhibits the synthesis of ergosterol, a vital component of fungal cell membranes, by blocking the cytochrome P450-dependent enzyme lanosterol 14α-demethylase.","indications":["Treatment of systemic fungal infections such as blastomycosis, coccidioidomycosis, histoplasmosis, and aspergillosis"],"catalyst":""},{"name":"OXY/APAP","genericName":"OXY/APAP","slug":"oxy-apap","phase":"phase_3","mechanism":"OXY/APAP combines oxycodone (an opioid analgesic) with acetaminophen (a non-opioid analgesic) to provide enhanced pain relief through dual mechanisms.","indications":["Moderate to severe acute pain"],"catalyst":""},{"name":"Oxycodone HCl controlled-release","genericName":"Oxycodone HCl controlled-release","slug":"oxycodone-hcl-controlled-release","phase":"marketed","mechanism":"Oxycodone HCl binds to opioid receptors in the central nervous system to block pain signal transmission and produce analgesia.","indications":["Moderate to severe chronic pain requiring continuous opioid therapy"],"catalyst":""},{"name":"Oxycodone/Naloxone controlled-release","genericName":"Oxycodone/Naloxone controlled-release","slug":"oxycodone-naloxone-controlled-release","phase":"phase_3","mechanism":"Oxycodone/naloxone is a controlled-release opioid analgesic combined with an opioid antagonist designed to provide pain relief while reducing abuse potential.","indications":["Moderate to severe chronic pain requiring continuous opioid therapy"],"catalyst":""},{"name":"Placebo oxycodone/acetaminophen tablets","genericName":"Placebo oxycodone/acetaminophen tablets","slug":"placebo-oxycodone-acetaminophen-tablets","phase":"phase_3","mechanism":"This is a placebo formulation containing no active pharmaceutical ingredients, used as a control in clinical trials to establish the true efficacy of oxycodone/acetaminophen combination therapy.","indications":["Control arm in clinical trials for opioid/acetaminophen combination pain relief"],"catalyst":""},{"name":"Placebo to match BTDS","genericName":"Placebo to match BTDS","slug":"placebo-to-match-btds","phase":"phase_3","mechanism":"This drug is a placebo that matches BTDS, meaning it has no active pharmacological effect.","indications":["Matching placebo for BTDS clinical trials"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxOYm04UWlUVFhsR3pHNlI1dW13Z3lNSnl4UXdZTVdRVU0wMC1qQzZQbl8wT0p3UXZpSUlKUF9nRm9jVmF0djk1WGEyYk81dk9DV3B1UTRRRjNJeXVhVDJZcDNMSzd4d3YtNjhJOTZEQ3UtblJpOUdhMXJmV3FCTVpvbWN3NE4wb3VEeHNvczU5SXdYUWIxQ3J0WmplNDNOSTF4YVFhTWFBX3oyRTBvdzItVUU3YVVWbUwtQXpfbXVuV3hDam51bHVkd2Nkd21VTmdsSW5McQ?oc=5","date":"2026-04-08","type":"trial","source":"PR Newswire","summary":"GCAR and Purdue Pharma L.P. Announce Initiation of Tinostamustine in GBM AGILE Trial - PR Newswire","headline":"GCAR and Purdue Pharma L.P. Announce Initiation of Tinostamustine in GBM AGILE Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE13d0Y1OGNyZUdSMVUwVktfRkliOER6SzVVM3lQbXlGM3dPVWhUc3JMZ3ZabzJaZXNsVjNVRnlZVXpzSVgta2dkSGhOSjRESTIwYTB4OWoyUjN2TTg?oc=5","date":"2026-02-26","type":"pipeline","source":"britannica.com","summary":"Sackler family | Brothers, OxyContin, Purdue Pharma, Opioid Epidemic, & Mundipharma - britannica.com","headline":"Sackler family | Brothers, OxyContin, Purdue Pharma, Opioid Epidemic, & Mundipharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxPcnNINl9wSWFDQk42VndOX2MyNjhLWFFUSjA1MDV3UngzTTg3WVFXNENQeXJuQ0hYckxPVThHLVhZSE44aEREUHFyQWh3ZDdGaFAxYVQ4QWkxcDdpY0J3cndzTi11djNQRHhsTzNBV3RtRWRpU1J3aEZvRWRtdTRCd3J0bmJESHFmYUNhSVRyRzhTT0s5VFhNdDFIX2l0aVZ5U0R4WHdfa242RDdveWdhZUc5VlRxcHhFbTdUSU1xRFV1eGxJYktMZWxrVTlDMmEwdXRid3VPNjF5UQ?oc=5","date":"2025-11-18","type":"regulatory","source":"PBS","summary":"Judge formally approves opioid settlement for Purdue Pharma and Sackler family members who own the company - PBS","headline":"Judge formally approves opioid settlement for Purdue Pharma and Sackler family members who own the company","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQZkFEMmJrODJPM25IcjNjQ0c1UXROSnVBd0UzaXd1OS1WUnZpOUhaVFk4OFBoMk80R3R4YkhFekw1UjVjay1zWmdyTGFQWTNBS3loQ1ZQWjJxZmJhRG5yYTBOaTNzazQzQ2Fnbm9QRnlieDdqWW15QlFxYlNUc1pmaGNmYjFTenloWVNDYXhvR0VTZmh5UEFtOUlXaUtYY2lCNTZFUzFsWU0?oc=5","date":"2025-11-14","type":"regulatory","source":"WSJ","summary":"Purdue Pharma Wins Court Approval for $7.4 Billion Opioid Settlement - WSJ","headline":"Purdue Pharma Wins Court Approval for $7.4 Billion Opioid Settlement","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPOFJXc21lemp0aENvZElfTE96WEZCV3NNbjJLd2dSejRUa044V2NwaDZ1NjFnTWgtMElUUEVacDZqUldWSmxXdFMtVkVsYjVSQzd2SGpraW5Ud2p2U0JhVFV4Z21IS0pZR3ozZ3JWZnNsRHhyR01ZanhJVm9NQVM5X2hmSHRmTDhPYjlJWXd6VHM3MERCMDE2M2FFQnJjZEt1ZXfSAacBQVVfeXFMTjZKOWJJeFVWb3dRWHJOdnlBMlJjaGtwTlA2dWw3Tllvd0JGM1JySlJMNkFRY1ZwSC1INGNoQzBPN3NyeUxmWVd2RUFWdHppSXJvc3NpREtUX2lCRFFDUkh4UDdpRVBIcndMaXphZVZWNFAyTUY3U01xdHFEVEYweXdmOVF6dlIza09YbGIzRWYxalhjbXNtWGVhQk04SGFvZ3otcEZkUnM?oc=5","date":"2025-11-14","type":"regulatory","source":"CNBC","summary":"U.S. judge to approve Purdue Pharma's opioid bankruptcy settlement - CNBC","headline":"U.S. judge to approve Purdue Pharma's opioid bankruptcy settlement","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOS1FzRjZqOERhWXROcTRCNkR2Rk9ZVUJWVUtVcjV1R3NIVVBxakxuS082WkRLeDZENzNINkhuYU9HVUdZbzdZVjVpbjBPbGZITHN3UmdtQUxzQUU4YjlTbllGWERXbjNmLTA1blFhRFRvWU1yQk4wUTZnaDRUbzNNWnMzbVFzTXY5a1RkV0lqek9oakdYb19jOGoweFdtTVNFTHlOdXhtdlBkeXFXMHlnbFNR?oc=5","date":"2025-11-14","type":"deal","source":"Bloomberg.com","summary":"Purdue Pharma Gets Court Nod for Bankruptcy Exit, Sackler Deal - Bloomberg.com","headline":"Purdue Pharma Gets Court Nod for Bankruptcy Exit, Sackler Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPM21LT3RmWnRVQWxPNkNwcFVqY2VlS2xHSlZGZjliVlN4cVdhWkR6VGNfSG9sY0lxTU5lUkoxekdQcDAwNnIyTVJpTUQ5dzlSVlkweFZYeGFOckU5aHFOdWRlNVYwMWlfdEs0dkc5eDhxODFQVlNtVzdkNWczaENFNjNnc25fQ20zTTZwYjl3Q0JXWmM5aW91M0QydkktMzBWTnF2NUpjNlQ1ZEZaaEVHMWZPX1BpSjlPeXB3NHF1TVZzSjht?oc=5","date":"2025-11-12","type":"regulatory","source":"reuters.com","summary":"Purdue Pharma urges bankruptcy judge to approve $7.4 billion opioid settlement - reuters.com","headline":"Purdue Pharma urges bankruptcy judge to approve $7.4 billion opioid settlement","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQSUMzNWtQWkt0MW9oencyOXB2U2lwcXJYbmNVT01mMFgxMlJWaWxyYjZZQUQ4RjRnU3YxaFpFVFRBYkhKOThleTFJcWdWaE9VQklreU9UeU04X2JzeXU3RzJMNXFFZzZKU01iajBtYmMxZ1VCRzQ3ZGt6RUpCTlR6SFJHb0RsdUlOeWFnRXpwVFdtNXpmMEtxN05PbFFxMnZQREdDUDI1OA?oc=5","date":"2025-11-12","type":"pipeline","source":"Bloomberg Law News","summary":"Purdue Pharma Lays Out Case for $7.4 Billion Bankruptcy Plan - Bloomberg Law News","headline":"Purdue Pharma Lays Out Case for $7.4 Billion Bankruptcy Plan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOX0U1QWF6YU5BNEJHRTZxMlkxM2tHOGhHeGpfcmlMejN6XzRUelZ6eHZQZzFVSjNSODE0aXVueWltNWRXVXE3dmoxeGpES2VWNHpGdV9mbFluSVl1Y19yUmRtRnpCdVdkc0FyU3g0djlCc2M2NEIxNmdzT0twZWxNOUNkQVpjYWZtN0hxZ3F3Q19rblloODRSTy1mS3hQc0F3a1ZFd1FONHotSE1OWjAweUo3YzU?oc=5","date":"2025-10-21","type":"pipeline","source":"citybiz","summary":"Purdue Pharma Plan of Reorganization Receives Overwhelming Creditor Support - citybiz","headline":"Purdue Pharma Plan of Reorganization Receives Overwhelming Creditor Support","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxQendGa2Zwb3gtcVFkb0tGaldIMVRLVlBPRVdyZWRmYXlYeGlMTkVBNklDRkZhaXlhOVV4dUJscGFJLWRyMVh3N2xpNW1ESGtwSnQ4QXV6a19CVTRyVXVJT29GanJVZnhzNkxleGdnTEltNkVMejZnT3Z6VVBPTzZyaTh2NlRwbEs2REd6Wm9qeHVXN3Vvd2R0eEZYbjhteVdMUHZLR19Xc1ljZ0tKVUNWWDRFTXhDanV3SEwxMHdqd0wtRldDT1RHVXpTc1NkWlHSAdQBQVVfeXFMT2habUt1T1lndDJFaEhDeHVWUEZTRHcwakV0NTEyZFYwWEY4R2lXZVJSRzR3a0puUDB4VDJaTHJIMUtHdmtKSEh4S3hqUjBRcVI3cmo0Mkc1Qlo4QU5LaC02TGkyZnhwWVJ6bWVycVFnZ3o1dWxyUlFrdzdNY01HOVZzZkd3RWdZM0EtWEVKdEs0YUFSZzB2dFpRSy04ZnI5TU9WTDdVeFZoU2dOcFNXUVdqY3hmVmJBSm4yVkVHNWpESGhJOGk5Rml3YlhGZF9QMWVwQjQ?oc=5","date":"2025-06-18","type":"pipeline","source":"PBS","summary":"OxyContin maker Purdue Pharma asks court to clear way for $7 billion settlement if states back it - PBS","headline":"OxyContin maker Purdue Pharma asks court to clear way for $7 billion settlement if states back it","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOY2pHMWRHT2pfY0M5SG1BWGRxTTZSZE9TaVZRUFpNU040SjhrbVVLaHpxUWJ3N1lVbnFnWGV5WERrVkJaSGtDYUI2alBTN3lpRXlwV3I2Znp1eHBnaGJENlFib2JqOXZxMGxPLWNEdi1HcGNfc3JuNWlKazFJMnRSM3cwN3ZxVlVkOU1YR0liMjNRYmJtenF5TmU3T1Ztd0RYWWZmVmstNA?oc=5","date":"2025-06-17","type":"pipeline","source":"thewellnews.com","summary":"Purdue Pharma to Pay $7.4B Over Its Sales of Painkiller OxyContin - thewellnews.com","headline":"Purdue Pharma to Pay $7.4B Over Its Sales of Painkiller OxyContin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPTVlPT1JHWG1kYjhhZ0Z5OUt1TmFELXJEWloxcmZuSFNJV3VMUGF3MXR6d1d1THVnMDc4SnFpZjhSYTV6Q2lmLWc1SmdWUDdXQV9NMWJLQ0ExV0pUZG1McFdQbU94aXhldlhTMTR3TU1Tc3RwVUVSRzhjQXpQR1haREdWUkFNUGFYZnpwMWtvR1BqSlZJUzc4X21hZGtITG00R0hyd0pLcXNwTHN4T3hvQTJGQVpMd9IBuwFBVV95cUxNYUdnMmQtRXZBNXpZWmJsamlvMExKa3BqMUZpUk5lMHdhQVhsaFA3LWxpa1dhRFkzSzhpb3Z5Rk1Va1ItTm9OdjJ5UW1DVE9vQmZVZWUwOC1rRzJnTnRHeGtXYjg0WnNlUTg3bEVBVjlWamlJb0V0ZlE5SnUxbFhMcDBxcW9vNmRSM0NiYnd3Ry1ubll3eUNZVExKTmNvelJMTjk2dWQyUVpsSU1wSGFSWUJ0TmNOcVp4RU1r?oc=5","date":"2025-06-16","type":"pipeline","source":"Al Jazeera","summary":"Purdue Pharma $7.4bn opioid settlement wins broad support from US states - Al Jazeera","headline":"Purdue Pharma $7.4bn opioid settlement wins broad support from US states","sentiment":"neutral"}],"patents":[{"drugName":"Subutex","drugSlug":"buprenorphine","patentNumber":"8236755","type":"Formulation","expiryDate":"2026-07-31","territory":"US","annualRevenue":800000000,"genericFilings":[]},{"drugName":"Subutex","drugSlug":"buprenorphine","patentNumber":"8236292","type":"Formulation","expiryDate":"2027-01-10","territory":"US","annualRevenue":800000000,"genericFilings":[]},{"drugName":"Subutex","drugSlug":"buprenorphine","patentNumber":"9827241","type":"Formulation","expiryDate":"2031-06-06","territory":"US","annualRevenue":800000000,"genericFilings":[]},{"drugName":"Subutex","drugSlug":"buprenorphine","patentNumber":"9782402","type":"Formulation","expiryDate":"2031-06-06","territory":"US","annualRevenue":800000000,"genericFilings":[]},{"drugName":"Subutex","drugSlug":"buprenorphine","patentNumber":"9272044","type":"Method of Use","expiryDate":"2031-06-06","territory":"US","annualRevenue":800000000,"genericFilings":[]},{"drugName":"Subutex","drugSlug":"buprenorphine","patentNumber":"9498432","type":"Formulation","expiryDate":"2031-06-06","territory":"US","annualRevenue":800000000,"genericFilings":[]},{"drugName":"Subutex","drugSlug":"buprenorphine","patentNumber":"10198218","type":"Method of Use","expiryDate":"2031-06-06","territory":"US","annualRevenue":800000000,"genericFilings":[]},{"drugName":"Subutex","drugSlug":"buprenorphine","patentNumber":"10592168","type":"Method of Use","expiryDate":"2031-06-06","territory":"US","annualRevenue":800000000,"genericFilings":[]},{"drugName":"Subutex","drugSlug":"buprenorphine","patentNumber":"10558394","type":"Formulation","expiryDate":"2031-06-25","territory":"US","annualRevenue":800000000,"genericFilings":[]},{"drugName":"Subutex","drugSlug":"buprenorphine","patentNumber":"8975270","type":"Formulation","expiryDate":"2031-09-05","territory":"US","annualRevenue":800000000,"genericFilings":[]},{"drugName":"Subutex","drugSlug":"buprenorphine","patentNumber":"8921387","type":"Formulation","expiryDate":"2032-01-06","territory":"US","annualRevenue":800000000,"genericFilings":[]},{"drugName":"Subutex","drugSlug":"buprenorphine","patentNumber":"12318379","type":"Formulation","expiryDate":"2032-07-26","territory":"US","annualRevenue":800000000,"genericFilings":[]},{"drugName":"Subutex","drugSlug":"buprenorphine","patentNumber":"12161640","type":"Formulation","expiryDate":"2032-07-26","territory":"US","annualRevenue":800000000,"genericFilings":[]},{"drugName":"Subutex","drugSlug":"buprenorphine","patentNumber":"11110084","type":"Formulation","expiryDate":"2032-07-26","territory":"US","annualRevenue":800000000,"genericFilings":[]},{"drugName":"Subutex","drugSlug":"buprenorphine","patentNumber":"10912772","type":"Method of Use","expiryDate":"2032-07-26","territory":"US","annualRevenue":800000000,"genericFilings":[]},{"drugName":"Subutex","drugSlug":"buprenorphine","patentNumber":"9937164","type":"Formulation","expiryDate":"2032-07-26","territory":"US","annualRevenue":800000000,"genericFilings":[]},{"drugName":"Subutex","drugSlug":"buprenorphine","patentNumber":"11135215","type":"Formulation","expiryDate":"2032-07-26","territory":"US","annualRevenue":800000000,"genericFilings":[]},{"drugName":"Subutex","drugSlug":"buprenorphine","patentNumber":"11000520","type":"Method of Use","expiryDate":"2035-11-06","territory":"US","annualRevenue":800000000,"genericFilings":[]},{"drugName":"Subutex","drugSlug":"buprenorphine","patentNumber":"11839611","type":"Method of Use","expiryDate":"2035-11-06","territory":"US","annualRevenue":800000000,"genericFilings":[]},{"drugName":"Subutex","drugSlug":"buprenorphine","patentNumber":"10646484","type":"Method of Use","expiryDate":"2038-06-22","territory":"US","annualRevenue":800000000,"genericFilings":[]}],"drugCount":13,"phaseCounts":{"marketed":6,"phase_3":6,"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}